Tuesday, October 28, 2025
- 10:30AM-12:30PM
-
Abstract Number: 1975
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
(1972–1989) Measures & Measurement of Healthcare Quality Poster II- 10:30AM-12:30PM
-
Abstract Number: 2028
Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III- 10:30AM-12:30PM
-
Abstract Number: 2535
Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III- 10:30AM-12:30PM
-
Abstract Number: 2453
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2439
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2513
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
(2504–2523) Vasculitis – ANCA-Associated Poster III- 10:30AM-12:30PM
-
Abstract Number: 2358
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2374
Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2341
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2347
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2345
Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2152
Blau Syndrome: features beyond the classic triad and proposal for clinical criteria
(2124–2158) Pediatric Rheumatology – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2476
Blinatumomab in rapid progressive systemic sclerosis
(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 1997
Bone health in patients with gout using real-world U.S. data